Access the full text.
Sign up today, get DeepDyve free for 14 days.
Alice Lam (2002)
Alternative societal models of learning and innovation in the knowledge economyInternational Social Science Journal, 54
T. Naka, K. Kubo (1999)
A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.Current pharmaceutical design, 5 6
H. Gatignon, M. Tushman, Wendy Smith, P. Anderson (2002)
A Structural Approach to Assessing Innovation: Construct Development of Innovation Locus, Type, and CharacteristicsManag. Sci., 48
Carla O'Dell, C. Grayson (1998)
If Only We Knew What We Know: Identification and Transfer of Internal Best PracticesCalifornia Management Review, 40
S. Zahra, Eric Gedajlovic, Donald Neubaum, Joel Shulman (2009)
A Typology of Social Entrepreneurs: Motives, search Processes and Ethical ChallengesJournal of Business Venturing, 24
Andrew Hargadon, R. Sutton (1997)
Technology brokering and innovation in a product development firm.Administrative Science Quarterly, 42
Nippon Rinsho, 51
Yuan Li, Yi Liu, Mingfang Li, Haibin Wu (2008)
Transformational offshore outsourcing: Empirical evidence from alliances in ChinaJournal of Operations Management, 26
M. Hara, R. Kiyama, S. Nakajima, T. Kawabata, M. Kawakami, K. Ohtani, K. Itazaki, T. Fujishita, M. Fujimoto (1995)
Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor.European journal of pharmacology, 289 2
Y. Inada, T. Wada, Y. Shibouta, K. Nishikawa (1993)
[Nonpeptide angiotensin II receptor antagonists].Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 38 11
P. Li (2010)
Toward a learning-based view of internationalization: The accelerated trajectories of cross-border learning for latecomersJournal of International Management, 16
Daniel Levinthal, J. March (1993)
The myopia of learningSouthern Medical Journal, 14
T. Naka (1993)
[Angiotensin II receptor antagonist activities and mode of action of benzimidazole-7-carboxylic acid derivatives].Nihon rinsho. Japanese journal of clinical medicine, 51 6
J. March (1991)
Exploration and Exploitation in Organizational LearningOrganization Science, 2
Jp Hughes, S. Rees, SB Kalindjian, KL Philpott (2011)
Principles of early drug discoveryBritish Journal of Pharmacology, 162
R. Dewar, J. Dutton (1986)
The Adoption of Radical and Incremental Innovations: An Empirical AnalysisManagement Science, 32
A. Gambardella (1995)
Science and innovation: Science and innovation in pharmaceutical research
Janine Nahapiet, S. Ghoshal (1998)
Social Capital, Intellectual Capital, and the Organizational AdvantageAcademy of Management Review, 23
G. Dosi (1982)
Technological Paradigms and Technological Trajectories: A Suggested Interpretation of the Determinants and Directions of Technical ChangeResearch Policy, 11
Huachu Liu (2014)
Tacit Knowledge Management and Its Philosophical Analysis
Technological Forecasting & Social Change, 76
Khaled Aboulnasr, Om Narasimhan, Edward Blair, Rajesh Chandy (2008)
Competitive Response to Radical Product InnovationsJournal of Marketing, 72
Ronald Mascitelli (2000)
From Experience: Harnessing Tacit Knowledge to Achieve Breakthrough InnovationJournal of Product Innovation Management, 17
T. Hara (2003)
Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development
Sheena Carlisle, M. Kunc, Eleri Jones, S. Tiffin (2013)
Supporting innovation for tourism development through multi-stakeholder approaches: Experiences from AfricaTourism Management, 35
I. Nonaka (1994)
A Dynamic Theory of Organizational Knowledge CreationOrganization Science, 5
M. Shibasaki, A. Fujimori, M. Takanashi, T. Kusayama, T. Tokioka, Y. Satoh*, T. Okazaki, W. Uchida, O. Inagaki, I. Yanagisawa (1997)
Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist.European journal of pharmacology, 335 2-3
W. Abernathy (2003)
Innovation : Mapping the winds of creative destruction *
Protein, Nucleic Acid and Enzyme, 38
R. Leifer, G. O'Connor, M. Rice (2001)
Implementing radical innovation in mature firms: The role of hubsAcademy of Management Perspectives, 15
E. Simon, D. Mckeough, A. Ayers, Ed Rinehart, B. Alexia (2003)
Managers at Work: How Do You Best Organize for Radical Innovation?Research-Technology Management, 46
David Collis (1994)
Research Note: How Valuable are Organizational Capabilities?Southern Medical Journal, 15
S. Snell, J. Dean (1992)
Integrated Manufacturing and Human Resource Management: A Human Capital PerspectiveAcademy of Management Journal, 35
Mohan Subramaniam, M. Youndt (2005)
The Influence of Intellectual Capital on the Types of Innovative CapabilitiesAcademy of Management Journal, 48
Mary Benner, M. Tushman (2003)
Exploitation, Exploration, and Process Management: The Productivity Dilemma RevisitedAcademy of Management Review, 28
D. Leonard, Sylvia Sensiper (1998)
The Role of Tacit Knowledge in Group InnovationCalifornia Management Review, 40
Economics of Innovation and New Technology, 7
L. Zucker, M. Darby (1998)
Capturing Technological Opportunity Via Japan's Star Scientists: Evidence from Japanese Firms' Biotech Patents and ProductsThe Journal of Technology Transfer, 26
Business Insights (2011)
The cardiovascular market outlook to 2016
Jamal Shamsie, Michael Mannor (2013)
Looking Inside the Dream Team: Probing Into the Contributions of Tacit Knowledge as an Organizational ResourceOrgan. Sci., 24
F. García-Muiña, E. Pelechano-Barahona, J. Navas-López (2007)
Knowledge Codification and Technological Innovation Success: Empirical Evidence from Spanish Biotech CompaniesPICMET '07 - 2007 Portland International Conference on Management of Engineering & Technology
Rajesh Chandy, G. Tellis (2000)
The Incumbent's Curse? Incumbency, Size, and Radical Product InnovationJournal of Marketing, 64
Biomedicine & Therapeutics, 43
Kent Miller, Meng Zhao, R. Calantone (2006)
Adding Interpersonal Learning and Tacit Knowledge to March's Exploration-Exploitation ModelAcademy of Management Journal, 49
Bruno Crépon, Emmanuel Duguet, J. Mairesse (1998)
Research, Innovation, and Productivity: an Econometric Analysis at the Firm LevelNBER Working Paper Series
Gabriel Szulanski (1996)
Exploring internal stickiness: Impediments to the transfer of best practice within the firmSouthern Medical Journal, 17
J. Senker (1995)
Tacit Knowledge and Models of InnovationIndustrial and Corporate Change, 4
I. Nonaka, H. Takeuchi (1995)
How Japanese Companies Create the Dynamics of Innovation
I. Liefde, Georges Vauquelin (2009)
Sartan–AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonismMolecular and Cellular Endocrinology, 302
RA Prentis, Y. Lis, SR Walker (1988)
Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).British journal of clinical pharmacology, 25 3
K. Zhou, C. Li (2012)
How knowledge affects radical innovation: Knowledge base, market knowledge acquisition, and internal knowledge sharingSouthern Medical Journal, 33
K. Atuahene-Gima (2005)
Resolving the Capability–Rigidity Paradox in New Product InnovationJournal of Marketing, 69
Strategic Management Journal, 14
M. Crossan, Iris Berdrow (2003)
Organizational learning and strategic renewalStrategic Management Journal, 24
R. Leifer (2000)
Radical Innovation: How Mature Companies Can Outsmart Upstarts
P. Chathoth, L. Altınay, R. Harrington, F. Okumus, E. Chan (2013)
Co-production versus co-creation: A process based continuum in the hotel service contextInternational Journal of Hospitality Management, 32
I. Kola, John Landis (2004)
Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 3
C. Banbury, W. Mitchell (1995)
The effect of introducing important incremental innovations on market share and business survivalSouthern Medical Journal, 16
Christian Sternitzke (2010)
Knowledge sources, patent protection, and commercialization of pharmaceutical innovations☆Research Policy, 39
Morten Hansen, N. Nohria, T. Tierney (1999)
What's your strategy for managing knowledge?Harvard business review, 77 2
M. Zack (1999)
Managing Codified KnowledgeSloan Management Review, 40
P. Timmermans, D. Carini, A. Chiu, J. Duncia, W. Price, G. Wells, P. Wong, R. Wexler, A. Johnson (1990)
Nonpeptide angiotensin II receptor antagonists.American journal of hypertension, 3 8 Pt 1
I. Nonaka, R. Toyama, N. Konno (2000)
SECI, Ba and Leadership: a Unified Model of Dynamic Knowledge CreationLong Range Planning, 33
Drug Design and Discovery, 16
Silvio Popadiuk, Chun Choo (2006)
Innovation and knowledge creation: How are these concepts related?Int. J. Inf. Manag., 26
M. Tushman, C. O'Reilly (1996)
Ambidextrous Organizations: Managing Evolutionary and Revolutionary ChangeCalifornia Management Review, 38
C. Medlin (2007)
Case Study Research
J. Spender (1996)
Making knowledge the basis of a dynamic theory of the firmSouthern Medical Journal, 17
Journal of Blood Pressure, 14
J. Ettlie (1983)
Organizational Policy and Innovation Among Suppliers to the Food Processing SectorAcademy of Management Journal, 26
Julia Nieves, J. Osorio (2013)
The role of social networks in knowledge creationKnowledge Management Research & Practice, 11
C. Hallin, Einar Marnburg (2008)
Knowledge management in the hospitality industry: A review of empirical researchTourism Management, 29
T. Naka, K. Kubo, K. Nishikawa, Y. Inada, Y. Furukawa (2000)
[Angiotensin II receptor antagonists: candesartan cilexetil].Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 120 12
Hsing-Er Lin, E. McDonough, S. Lin, C. Lin (2013)
Managing the Exploitation/Exploration Paradox: The Role of a Learning Capability and Innovation AmbidexterityJournal of Product Innovation Management, 30
J. Johannessen, Bjørn Olsen, G. Lumpkin (2001)
Innovation as newness: what is new, how new, and new to whom?European Journal of Innovation Management, 4
M. Tushman, Philip Anderson (1986)
Technological Discontinuities and Organizational EnvironmentsAdministrative Science Quarterly, 31
PurposeThe purpose of this paper is to examine the role of tacit knowledge in incremental innovation, which has hitherto been neglected.Design/methodology/approachQualitative case analysis was used to focus on two large Japanese pharmaceutical companies’ development of new antihypertensive drugs. The study uses interview data and documentary research materials to explore the knowledge bases of the companies’ research teams as they refined an existing drug to produce new products – a process of incremental innovation.FindingsExplicit knowledge (chemical structure of preceding drug) was used in both successful and failed cases of drug discovery. In the two successful cases, the tacit knowledge of key researchers, based on their long-term experience of related research, provided insight into developing compounds with good in vivo efficacy, which led to successful clinical development.Practical implicationsThe findings suggest that tacit knowledge may play an important role in incremental innovation processes, and that its influence on product development should be considered in such ways as team and organization structure.Originality/valueThis study addresses a gap in the literature regarding the impact of tacit knowledge on incremental innovation processes. It is often assumed that incremental innovation is based on existing technology. This study suggests that tacit knowledge may play a hitherto largely unrecognized role in incremental product development.
Journal of Strategy and Management – Emerald Publishing
Published: Feb 20, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.